QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.054320v1 307/2/699    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tallarida, R. J. Articles by Raffa, R. B. Search for Related Content PubMed PubMed Citation Articles by Tallarida, R. J. Articles by Raffa, R. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB ACETAMINOPHEN ACETYLSALICYLIC ACID IBUPROFEN INDOMETHACIN Medline Plus Health Information Pain Pain Relievers

NEUROPHARMACOLOGY

Antinociceptive Synergy, Additivity, and Subadditivity with Combinations of Oral Glucosamine Plus Nonopioid Analgesics in Mice

Temple University School of Medicine (R.J.T., A.C., R.B.R.) and Temple University School of Pharmacy (R.B.R.), Philadelphia, Pennsylvania

Glucosamine (2-amino-2-deoxy-D-glucose) and glucosamine-containing products have been reported to have efficacy in the treatment of various musculoskeletal disorders. Glucosamine's efficacy, including reduction of pain, is attributed to disease-modifying properties, specifically to cartilage-rebuilding associated with modulation of interleukin-1-induced activation of chondrocytes and to inhibition of proinflammatory effects of the nuclear factor-B pathway. However, glucosamine has not been shown to have direct analgesic activity. We report here that commercial glucosamine (90.4% glucosamine sulfate + 9.6% excipients) administered as the sole agent (up to 500 mg/kg p.o.) was inactive in the mouse abdominal irritant test but that certain combinations of glucosamine with nonopioid analgesics at the oral doses and ratios tested resulted in a synergistic (ibuprofen and ketoprofen), additive (diclofenac, indomethacin, naproxen, and piroxicam), or subadditive (aspirin and acetaminophen) antinociceptive interaction. In the specific case of ibuprofen, the racemate (standard ibuprofen) produced dose-related antinociception with ED₅₀ = 26.1 ± 3.4 mg/kg. Combinations containing racemic ibuprofen and glucosamine in greater than 1:1 ratio (glucosamine/ibuprofen) were synergistic in the test (e.g., ED₅₀ = 11.0 ± 2.1 for the 9:1 ratio; p < 0.01, analysis of variance). Combinations containing glucosamine and ibuprofen (2:1 and 9:1) yielded plasma levels of ibuprofen that were no different from administration of ibuprofen alone. The possibility that combinations containing certain fixed ratios of glucosamine and certain nonsteroidal anti-inflammatory drugs (NSAIDs) might enhance pain relief in patients with pain or might achieve acceptable levels of pain relief with lower doses of NSAIDs (reduced adverse effects) is presently being pursued in clinical trials.

Address correspondence to: Dr. Ronald J. Tallarida, Department of Pharmacology, Temple University School of Medicine, 3420 N. Broad St., Philadelphia, PA 19140-5104. E-mail: ronald.tallarida{at}temple.edu

This article has been cited by other articles:

				R. J. Tallarida An Overview of Drug Combination Analysis with Isobolograms J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 1 - 7. [Abstract] [Full Text] [PDF]

				G.-X. Zhang, S. Yu, B. Gran, and A. Rostami Glucosamine Abrogates the Acute Phase of Experimental Autoimmune Encephalomyelitis by Induction of Th2 Response J. Immunol., December 1, 2005; 175(11): 7202 - 7208. [Abstract] [Full Text] [PDF]